[Evolution in the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma].
Pancreatic ductal adenocarcinoma is characterized by a high rate of early metastatic relapse. Surgical resection is still recognized as the cornerstone upfront therapy. However, reported 5 years survival rates are inferior to 20-25% even when surgery is followed by chemotherapy. Margins involvement on the surgical specimen (50 to 85%) and lymph node involvement (around 70%) both strongly impact survival. Median survivals are close to those of locally advanced diseases treated by chemotherapy or chemoradiotherapy, 15 to 16 months. This review focuses on adverse prognostic factors, post-operative outcomes and their impact on multimodality therapy completion rates and survivals in patients undergoing upfront surgery. Current data and emerging results from neoadjuvant series could lead to a change in the therapeutic strategy.
D
D
Van Daele
F
F
Puleo
R
R
Dumont
M
M
Polus
C
C
Loly
P
P
Martinive
P
P
Meunier
J
J
Collignon
A
A
Hendlisz
R
R
Maréchal
E
E
Louis
J-L
JL
Van Laethem
D021441:Carcinoma, Pancreatic Ductal / Q000628:therapy*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000628:therapy*